AGENUS INC Non Peo Neo Avg Total Comp Amt
AGENUS INC (AGEN) reported Non Peo Neo Avg Total Comp Amt of $617.42 thousand for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-30.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-30
| Period end | Non Peo Neo Avg Total Comp Amt 12 month | Non Peo Neo Avg Total Comp Amt 12 month as first filed |
|---|---|---|
| 2025-12-31 | $617.42K DEF 14A · filed 2026-04-30 | $468.70K PRE 14A · filed 2026-04-20 |
| 2024-12-31 | $926.89K DEF 14A · filed 2026-04-30 | |
| 2023-12-31 | $1.07M DEF 14A · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |